VaxInnate Reports Positive Results From Preclinical Testing Of Swine Flu Vaccine Developed Using Novel Technology
(No Ratings Yet)
Loading ...
June 18, 2009 by fluoutbreak
VaxInnate Corporation today reported positive preclinical results for a recombinant swine flu vaccine it developed in less than three weeks, making it one of the first companies in the world to begin testing a vaccine that could help halt the spread of the swine flu pandemic. Preclinical studies in mice suggest that VaxInnate’s recombinant swine flu vaccine could provide protection against the pandemic H1N1 influenza A swine flu strain, VaxInnate CEO Alan Shaw , PhD told attendees at the 7th Annual Biodefense Vaccines and Therapeutics meeting taking place here. Further preclinical testing of the vaccine is already underway.
“Using our novel vaccine technology, VaxInnate was able to rapidly develop and begin testing a vaccine that could be a useful weapon against the pandemic flu,” Dr. Shaw said. “We’re encouraged by our results to date and are moving forward with further preclinical testing.
“In doing so, VaxInnate is hoping to partner with the U.S. government on further development of our swine flu vaccine,” he added. “The federally-funded vaccine technologies in development cannot produce vaccines as rapidly and efficiently as VaxInnate can, and we want the opportunity to demonstrate our capabilities.”
Dr. Shaw said VaxInnate is also seeking international partners for the development of this and other pandemic vaccines to meet global needs. VaxInnate’s announcement comes less than a week after the World Health Organization (WHO) declared the first flu pandemic in 41 years.
Loading ...
